ArticleSurgery today2025
Effect of ground-glass opacity components on the recurrence of pathological stage IB non-small cell lung cancer harboring epidermal growth factor receptor mutations.
Article in Surgery today, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Efficacy of Adjuvant EGFR-TKI Therapy for Stage IA Lung Adenocarcinoma with EGFR Mutations: A Retrospective Cohort Study.Annals of surgical oncology · 2026Article
- Adjuvant targeted therapy in high-risk stage IB epidermal growth factor receptor-mutant lung cancer: Role of ground-glass opacity components.JTCVS open · 2026Article
- Wedge resection versus segmentectomy in peripheral clinical stage IA lung cancer concerning ground-glass opacity.Surgery today · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeThis study aimed to examine the influence of ground-glass opacity (GGO) on the prognosis of epidermal growth factor receptor (EGFR)-mutated pathological (p)-stage IB non-small cell lung cancer (NSCLC).
methodsBetween 2009 and 2021, 115 patients underwent complete anatomical lung resection with mediastinal lymphadenectomy for p-stage IB non-squamous NSCLC harboring common EGFR mutations. The patients were classified into the part-solid and pure-solid arms based on the presence of GGO components.
resultsThe median follow-up time was 70.2 months. Sixty-seven patients (58%) had pure-solid tumors and 112 (97%) were diagnosed with adenocarcinoma. No patients received adjuvant EGFR-tyrosine kinase inhibitors (TKIs). The 5-year disease-free survival (DFS) rates in the pure-solid arm were significantly lower than those in the part-solid arm (5-year DFS: 45.3% vs. 86.8%, p < 0.01). The 5-year cumulative incidence of recurrence was higher in the pure-solid arm than that in the part-solid arm (49.9% vs. 9.0%, p < 0.01). A multivariable analysis revealed that pure-solid tumors were an independent prognostic predictor of disease-free survival, whereas pathological factors were not.
conclusionsIn EGFR-mutated p-stage IB NSCLC, pure-solid tumors were significant predictors of DFS. The presence of GGO components should be considered in the decision criteria for adjuvant therapy with TKIs.
Indexed as
Identifiers
39900640What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.